Clinical Efficacy of a Single Two Gram Dose of Azithromycin Extended Release for Male Patients with Urethritis

Antibiotics

Satoshi Takahashi¹  Hiroshi Kiyota²  Shin Ito⁴  Akihiko Iwasawa³  Yoshiki Hiyama¹  Teruhisa Uehara¹  Koji Ichihara¹  Jiro Hashimoto¹  Naoya Masumori¹  Kenichi Sunaoshi⁶  Koichi Takeda⁶  Nobukazu Suzuki⁶  Takahide Hosobe⁷  Hirokazu Goto⁵  Hidenori Suzuki⁵ 

[1] Department of Urology, Sapporo Medical University School of Medicine, S. 1, W. 16, Chuo-ku, Sapporo, Hokkaido 0608543, Japan; E-Mails:;Department of Urology, the Jikei University Katsushika Medical Center, 6-41-2 Aoto Katsushika-ku, Tokyo 1258506, Japan; E-Mail:;Iwasawa Clinic, Sapporo Medical University School of Medicine, S. 1, W. 16, Chuo-ku, Sapporo, Hokkaido 0600061, Japan; E-Mail:;iClinic, 5-9-6, Nagamachi, Taihaku-ku, Sendai, Miyagi 9820011, Japan; E-Mail:;Department of Urology, Fuji City General Hospital, 50 Takashima-Cho, Fuji, Shizuoka 4178567, Japan; E-Mails:;Teine Urologic Clinic, 1-12, Maeda 6-7, Teine-ku, Sapporo 0060816, Japan; E-Mails:;Hosobe Clinic, 1-1-15, Nezu, Bunkyo-ku, Tokyo 1130031, Japan; E-Mail:

关键词: azithromycin;    extended release;    urethritis;    Neisseria gonorrhoeae;    Chlamydia trachomatis;    Mycoplasma genitalium;    Ureaplasma urealyticum;   

DOI  :  10.3390/antibiotics3020109

来源: mdpi

【 摘 要 】

To clarify the clinical efficacy of a single oral 2 g dose of azithromycin extended-release for heterosexual male patients with urethritis, and the current antimicrobial sensitivity of Neisseria gonorrhoeae to azithromycin, a prospective clinical trial was conducted from 2011–2013. In patients with gonococcal urethritis, the eradication rate was 90.9% (30 of 33). The susceptibility rates of isolated Neisseria gonorrhoeae strains to ceftriaxone, spectinomycin, cefixime and azithromycin were 100%, 100%, 95.3% (41/43) and 37.2% (16/43), respectively. In the patients with nongonococcal urethritis, the eradication rate was 90.0% (45 of 50). The microbiological eradication rates for the pathogens were 90.9% (30/33) for Neisseria gonorrhoeae, 91.5% (43/47) for Chlamydia trachomatis, 71.4% (5/7) for Mycoplasma genitalium, and 100% (13/13) for Ureaplasma urealyticum. The main adverse event was diarrhea and its manifestation rate was 35.2% (32 of 120). The symptom of diarrhea was mostly temporary and resolved spontaneously. The conclusion was that the treatment regimen with a single oral 2 g dose of azithromycin extended-release would be effective for patients with urethritis. However, the antimicrobial susceptibilities of Neisseria gonorrhoeae and Mycoplasma genitalium should be carefully monitored because of possible treatment failure.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.